Company research
Scribe Therapeutics, Inc.
CIK 1853921Updated Nov 13, 2026
SecuritySCTX · NASDAQ · equity
SCTX price & chart
Loading TradingView…
NASDAQ:SCTX on TradingView ↗About the company
We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. We are designing CRISPR-based genetic medicines to be well-tolerated, effective, durable, and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention, with the goal of broadly democratizing access to the cardioprotective effects of known genetic variants. Our lead product candidate, STX-1150, utilizes ELXR, our highly engineered epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reduction…
In the news
No coverage from other publishers is available.
Seeking Alpha
Crispr Therapeutics: The Recent 40% Drop In Short Interest Indicates Deteriorating Bearish Sentiment ↗
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast ↗
SEC disclosures
Scribe Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
Offerings
Registration 333-297246
- Gross proceeds
- 128700000.0
- Net proceeds
- 119691000.0
- Deal price
- 15.0
- Shares
- 8580000
- Offering price
- $15.00
- Ticker
- SCTX
Underwriters: Leerink Partners LLC, Goldman Sachs & Co. LLC, Guggenheim Securities, LLC, Wells Fargo Securities, LLC
Registration 333-297661
Filing attachments
sctx-ex99_1.htm · 8-K · 2026-11-12
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400 Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the Company’s epigenetic silencing therapy for LDL-C lowering, with initial clinical data expected in the first half of 2027 Expanded strategic collaboration wit…
Read attachment ↗sctx-ex99_1.htm · 8-K · 2026-09-02
EX-99.1 2 sctx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes Awarded more than $25 million from the California Institute for Regenerative Medicine (CI…
Read attachment ↗d21355dex991.htm · S-1/A · 2026-07-10
Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Scribe Therapeutics Inc. (the “Company”) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of the Company in the Registration Statement and any and all amendments and supplements thereto. I…
Read attachment ↗d21355dex107.htm · S-1 · 2026-07-02
EX-10.7 10 d21355dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 SCRIBE THERAPEUTICS INC. May 8, 2023 David Parrot Re: EMPLOYMENT AGREEMENT Dear David: This Employment Agreement (the “Agreement”) between you (referred to hereinafter as the “Executive”) and Scribe Therapeutics Inc., a Delaware corporation (the “Company”) sets forth the terms and conditions that shall govern the period of Executive’s continued employment with the Company (referred to hereinafter as “Employment” or the “E…
Read attachment ↗d21355dex41.htm · S-1 · 2026-07-02
EX-4.1 4 d21355dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SEE REVERSE FOR INCORPORATED UNDER THE CERTAIN DEFINITIONS LAWS OF THE STATE AND LEGENDS OF DELAWARE CUSIP XXXXX XX X This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF SCRIBE THERAPEUTICS INC. transferable on the books of the corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid un…
Read attachment ↗d21355dex42.htm · S-1 · 2026-07-02
EX-4.2 5 d21355dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 17th day of March, 2021, by and among Scribe Therapeutics Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, certain of the Investors (the “Existing Investors”) hold …
Read attachment ↗